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Abstract
Background: Chronic chorioamnionitis is found in more than one-third of spontaneous preterm births. Chronic
chorioamnionitis and villitis of unknown etiology represent maternal anti-fetal cellular rejection. Antibody-mediated
rejection is another type of transplantation rejection. We investigated whether there was evidence for antibody-mediated
rejection against the fetus in spontaneous preterm birth.
Methods and Findings: This cross-sectional study included women with (1) normal pregnancy and term delivery (n = 140)
and (2) spontaneous preterm delivery (n = 140). We analyzed maternal and fetal sera for panel-reactive anti-HLA class I and
class II antibodies, and determined C4d deposition on umbilical vein endothelium by immunohistochemistry. Maternal anti-
HLA class I seropositivity in spontaneous preterm births was higher than in normal term births (48.6% vs. 32.1%, p = 0.005).
Chronic chorioamnionitis was associated with a higher maternal anti-HLA class I seropositivity (p,0.01), significant in
preterm and term birth. Villitis of unknown etiology was associated with increased maternal and fetal anti-HLA class I and II
seropositivity (p,0.05, for each). Fetal anti-HLA seropositivity was closely related to maternal anti-HLA seropositivity in both
groups (p,0.01, for each). C4d deposition on umbilical vein endothelium was more frequent in preterm labor than term
labor (77.1% vs. 11.4%, p,0.001). Logistic regression analysis revealed that chronic chorioamnionitis (OR= 6.10, 95% CI
1.29–28.83), maternal anti-HLA class I seropositivity (OR= 5.90, 95% CI 1.60–21.83), and C4d deposition on umbilical vein
endothelium (OR= 36.19, 95% CI 11.42–114.66) were associated with preterm labor and delivery.
Conclusions: A major subset of spontaneous preterm births has a signature of maternal anti-fetal cellular and antibody-
mediated rejections with links to fetal graft-versus-host disease and alloimmune reactions.
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Introduction
Preterm birth is the leading cause of perinatal mortality and
morbidity worldwide [1]. Moreover, the rate of preterm birth has
been rising in most developed countries, ranging from 5% to 13%
of all deliveries [2,3]. The socioeconomic impact of preterm birth
cannot be overestimated, and the cost of preterm birth is $26
billion per year in the United States [4,5]. While preterm birth is
known to be associated with various obstetric disorders such as
intra-uterine infection/inflammation and preeclampsia [1,6], the
causes and precise mechanisms are not fully understood. A robust
clinico-pathologic classification of heterogeneous varieties of
preterm birth is fundamental to the diagnosis, prognosis, and
design of ideal therapeutic interventions. Therefore, the elucida-
tion of the essential pathophysiology of different types of preterm
birth is an urgent and important matter.
The fetus is the most successful semi-allograft. Maternal
immune tolerance of the fetus, therefore, is essential for successful
pregnancy [7,8]. Accordingly, failure of maternal tolerance to the
fetus has been suggested as a mechanism of adverse pregnancy
outcomes: recurrent pregnancy loss, fetal growth restriction, and
preeclampsia [9–11]. Allograft rejection involves both innate and
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adaptive immune mechanisms [12,13]. The most important
alloantigens, major histocompatibility complex (MHC) class I
and class II molecules, comprise the human leukocyte antigen
(HLA) system [12,14]. Transplantation rejection is initiated after
the recognition of donor alloantigens by recipient T cells via direct
or indirect pathways, which is followed by both cellular
(lymphocyte-mediated) and humoral (antibody-mediated) immune
responses [12]. The presence of circulating anti-HLA antibodies in
the recipient is a serious obstacle to successful organ transplan-
tation [15,16].
Chronic chorioamnionitis and villitis of unknown etiology of the
placenta are closely related immunologic inflammatory lesions,
harboring features of allograft rejection of the mother and graft-
versus-host disease of the fetus [17,18]. Chronic chorioamnionitis,
defined as lymphocytic infiltration of the chorioamniotic mem-
branes [19], is the most common lesion found in placentas of
spontaneous preterm births although it can also be found in a
small fraction (9%) of term births [18]. It is associated with a
robust increase in the amniotic fluid T cell chemokine CXCL10
concentration and CXCL9, CXCL10, and CXCL11 mRNA
expression in the chorioamniotic membranes [18]. The essential
feature of this inflammation is chemotaxis of T cells expressing
CXCR3, which is a receptor for CXCL9, CXCL10, and
CXCL11. CXCR3 mediates both chemotactic and anti-angio-
genic activities, and it is also expressed in natural killer cells and
macrophages. A unique feature of chronic chorioamnionitis and
villitis of unknown etiology is that fetal tissues - the chorioamniotic
membranes and chorionic villi - are infiltrated by maternal T cells.
Maternal origin of T cells in villitis of unknown etiology has been
elegantly shown by in situ hybridization [20]. Given that chronic
chorioamnionitis and villitis of unknown etiology are consistent
with maternal anti-fetal cellular rejection, we hypothesized that
maternal antibody-mediated rejection against the fetus could also
be associated with preterm labor and preterm prelabor rupture of
membranes. The clinical significance of anti-paternal HLA
antibodies in pregnant women has been mainly studied in the
settings of recurrent miscarriage but not in spontaneous preterm
birth [21–27]. The potential significance of maternal antibody-
mediated rejection against the fetus is two-fold as antibodies
crossing the placenta can induce a systemic fetal alloimmune
reaction as seen in Rh incompatibility and alloimmune thrombo-
cytopenia [28,29].
This cross-sectional study was conducted to examine the
frequency and significance of anti-HLA antibodies in maternal
and fetal sera according to the presence of chronic chorioamni-
onitis, particularly in the context of spontaneous preterm birth.
Methods
Study population
We studied 280 women with the following diagnoses: (1) normal
pregnancy and term delivery (n = 140): term not in labor (n = 70)
or term in labor (n = 70), and (2) spontaneous preterm delivery
(n = 140): preterm labor with intact membranes (n = 70) or
preterm prelabor rupture of membranes (n = 70). Fetal congenital
anomalies and cases with small-for-gestational-age neonates were
excluded from this study. Preterm labor was defined as the
presence of regular uterine contraction associated with cervical
dilatation, followed by delivery before 37 completed weeks of
gestation. Preterm prelabor rupture of membranes was diagnosed
by sterile speculum examination when pooling of amniotic fluid in
the vagina occurred or when positive nitrazine and ferning tests,
conducted when necessary, were confirmed before 37 weeks of
gestation in the absence of labor. Placental tissues and cord blood
samples were collected at the time of delivery, and maternal blood
samples were drawn and collected within 7 days before and after
delivery, which allowed us to maintain a meaningful temporal
relationship between placental pathology and the status of anti-
HLA antibodies in maternal and fetal sera. Samples were kept at
280uC until use.
All patients were Hispanic women who were enrolled and
delivered at the So´tero del Rio Hospital in Santiago, Chile. Serum
and tissue samples from all patients were retrieved from the Bank
of Biological Materials of the Perinatology Research Branch,
Eunice Kennedy Shriver National Institute of Child Health and
Human Development, National Institutes of Health, U. S.
Department of Health and Human Services. All women provided
written informed consent before participating in the study. The
use of clinical data and the collection and utilization of biological
samples for research purposes were approved by the Institutional
Review Boards of the So´tero del Rio Hospital, Santiago, Chile (an
affiliate of the Pontificia Universidad Cato´lica de Chile), Wayne
State University, and the Eunice Kennedy Shriver National Institute of
Child Health and Human Development, National Institutes of
Health, U.S. Department of Health and Human Services.
Placental pathology
Histopathological changes of the placenta were defined
according to diagnostic criteria proposed by the Perinatal Section
of the Society for Pediatric Pathology, which include lesions
consistent with amniotic fluid infection, maternal vascular under-
perfusion, and fetal vascular thrombo-occlusive disease [30].
Diagnosis of villitis of unknown etiology was based on histologic
criteria previously defined [17], and chronic chorioamnionitis was
diagnosed when lymphocytic infiltration into the chorionic
trophoblast layer or chorioamniotic connective tissue was present
as described previously [18].
Flow cytometry of panel-reactive anti-HLA antibodies
Flow cytometric analysis of panel-reactive anti-HLA class I and
class II antibodies in maternal and cord blood sera was performed
using the FlowPRAH-I screening test (One Lambda Inc., Canoga
Park, CA, USA) and FlowPRAH-II screening test (One Lambda
Inc.) according to the manufacturer’s instructions. Class I or class
II microbeads were mixed with 20 ml of serum, and incubated for
30 min at room temperature with gentle rotation. The beads were
washed 3 times with 1 ml of Flow PRA wash buffer by
centrifugation at 9,0006g for 2 min, followed by incubation with
100 ml of FITC-conjugated F(ab)2 fragment of Fcc fragment
specific goat anti-human IgG for 30 min. After washing the beads
twice with 1 ml of wash buffer and adding 0.5 ml of fixing solution
(PBS with 0.5% formaldehyde), the FL1 fluorescence of 5,000
events was analyzed using BD LSRII flow cytometry (BD
Biosciences, San Jose, CA, USA). A sample with reactivity of
10% or more was considered positive for panel-reactive anti-HLA
antibodies [31,32].
Immunohistochemistry
Immunohistochemistry assessed C4d deposition on umbilical
blood vessels. Five-mm-thick sections of formalin-fixed, paraffin-
embedded umbilical cords were placed on silanized slides and
stained using a Ventana Discovery automatic staining system
(Ventana Medical Systems, Tucson, AZ, USA). Immunostaining
was performed using a mouse monoclonal anti-human C4d
antibody (1:100, ALPCO Diagnostics, Salem, NH, USA). The
DiscoveryH DAB MapTM Kit (Ventana Medical Systems) detected
the chromogen reaction of horseradish peroxidase.
Anti-Fetal Rejection in Spontaneous Preterm Birth
PLoS ONE | www.plosone.org 2 February 2011 | Volume 6 | Issue 2 | e16806
Statistical analysis
The characteristics were examined to find differences between
women who had normal pregnancy and term delivery (n = 140)
and women who had spontaneous preterm delivery (n = 140). For
continuous variables, distributions were examined for normality
using Kolmogorov-Smirnov tests. When data were far from
normality, the Mann-Whitney U test was performed between
groups. If there was normality in continuous variables, an
unpaired t-test was used. For categorical variables, proportions
were compared with Fisher’s exact test or x2 test. Means and
standard errors of mean (SEMs) were reported for continuous
variables whereas frequencies and percentages were calculated for
categorical variables. The Spearman rank correlation test
determined the relationship between maternal and fetal anti-
HLA antibodies. Logistic regression analysis was performed to
determine (1) the relative effect of clinical variables and placental
pathology on maternal and fetal anti-HLA seropositivity and (2)
the effect of placental pathology, anti-HLA antibodies in maternal
and fetal sera, and C4d deposition on the occurrence of
spontaneous preterm birth. Statistical analyses were performed
using SPSS Version 15.0 (SPSS, Inc., Chicago, IL, USA). All p
values are two-sided, and a value of p,0.05 is considered to be
statistically significant.
Results
Table 1 shows the demographics of the study population. There
were significant differences in the proportion of cases with
placental changes (maternal vascular underperfusion and chronic
chorioamnionitis) between cases with normal term birth and
spontaneous preterm birth (p,0.01, for each). Differences were
observed in maternal age, gravidity, parity, and frequencies of
cesarean delivery (p,0.05, for each). Chronic chorioamnionitis is
histologically characterized by maternal T cell infiltration in the
chorionic trophoblast layer or chorioamniotic connective tissue
layer. Representative histological features are illustrated in
Figure 1.
Figure 2A illustrates the presence of anti-HLA class I antibodies
detected by flow cytometry in maternal serum of a representative
case. To determine whether anti-HLA antibodies play a role in
spontaneous preterm birth, anti-HLA seropositivity of women
presenting with spontaneous preterm birth was compared to cases
of normal term birth (Figure 2B). Spontaneous preterm birth had a
higher maternal anti-HLA class I seropositivity than normal
delivery at term (48.6% vs. 32.1%, p= 0.005). There was a
significant difference in maternal anti-HLA class I seropositivity
among cases classified in detail according to their clinical diagnosis
(cases with term in labor, 31.4%; cases with term not in labor,
32.9%; cases with preterm labor and intact membranes, 52.9%;
cases with preterm premature rupture of membranes, 44.3%;
p= 0.002).
Figure 3 shows the relationship between anti-HLA seropositivity
and placental pathology. When anti-HLA seropositivity was
compared according to placental pathology, maternal anti-HLA
class I and class II seropositivity and fetal anti-HLA class I
seropositivity were higher in chronic chorioamnionitis cases than
in those without chronic chorioamnionitis (for maternal anti-HLA
class I antibodies: 65.8% vs. 30.9%, p,0.001; for maternal anti-
HLA class II antibodies: 26.3% vs. 15.7%, p= 0.042; for fetal anti-
HLA class I antibodies: 30.3% vs. 15.2%, p= 0.004). Similarly,
cases with villitis of unknown etiology had higher maternal and
fetal anti-HLA class I and class II seropositivity than those without
(for maternal anti-HLA class I antibodies: 73.6% vs. 32.6%,
p,0.001; for maternal anti-HLA class II antibodies: 43.3% vs.
12.8%, p,0.001; for fetal anti-HLA class I antibodies: 47.2% vs.
12.8%, p,0.001). For other placental pathologic lesions consistent
with amniotic fluid infection, maternal vascular underperfusion,
and fetal vascular thrombo-occlusive disease, anti-HLA class I or
class II seropositivity was not different, with the exception that
maternal anti-HLA class I seropositivity was higher in cases with
maternal vascular underperfusion than in those without
(p = 0.036).
To determine the relative effects of clinical variables and
placental pathology on maternal and fetal anti-HLA seropositivity,
logistic regression analysis was performed. After adjusting for five
placental pathologic findings and clinical variables (e.g., gestation-
al age at delivery, maternal age, fetal gender, gravidity), chronic
chorioamnionitis, villitis of unknown etiology, and previous
Table 1. Demographics of study populations.
Term birth Spontaneous preterm birth
n=140 n=140 p
Maternal age (years)* 27.460.5 26.060.7 0.036
Primigravida (%) 15.7 (22/140) 42.9 (60/140) ,0.001
Nulliparous (%) 17.9 (25/140) 47.9 (67/140) ,0.001
Gestational age at delivery (weeks)* 39.560.1 34.060.2 ,0.001
Cesarean delivery (%) 50.0 (70/140) 22.1 (31/140) ,0.001
Birth weight (g)* 3416.7626.7 2377.4647.5 ,0.001
Baby gender (male sex) (%) 55.0 (77/140) 67.1 (94/140) 0.037
Placental pathology
Acute chorioamnionitis (%) 12.9 (18/140) 18.6 (26/140) NS
Maternal underperfusion (%) 2.1 (3/140) 12.9 (18/140) 0.001
Fetal vascular thrombo-occlusive disease (%) 6.4 (9/140) 6.4 (9/140) NS
Villitis of unknown etiology (%) 15.7 (22/140) 22.1 (31/140) NS
Chronic chorioamnionitis (%) 13.6 (19/140) 40.7 (57/140) ,0.001
*Mean6SEM.
doi:10.1371/journal.pone.0016806.t001
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pregnancy increased maternal anti-HLA class I seropositivity (for
chronic chorioamnionitis: OR 3.84, 95% CI 1.97–7.48, p,0.001;
for villitis of unknown etiology: OR 5.22, 95% CI 2.47–11.03,
p,0.001; for previous pregnancy: OR 2.63, 95% CI 1.20–5.78,
p = 0.016). Although the effects of chronic chorioamnionitis on
fetal anti-HLA class I antibody seropositivity did not reach
statistical significance (p = 0.102), villitis of unknown etiology
increased maternal anti-HLA class II seropositivity and anti-HLA
class I and II seropositivity in the fetus (p,0.05, for each).
The results from within-group comparisons were also consistent.
Maternal anti-HLA class I seropositivity was higher in chronic
chorioamnionitis cases than in those without chronic chorioamnio-
nitis both in normal term births (63.2% vs. 27.3%, p=0.002) and
spontaneous preterm births (66.7% vs. 36.1%, p,0.001). Maternal
anti-HLA class II seropositivity was higher in cases of normal term
birth with chronic chorioamnionitis than in cases without (42.1% vs.
14.0%, p=0.007). Fetal anti-HLA class I seropositivity was also
higher in spontaneous preterm birth cases with chronic chorioam-
nionitis than in those without this lesion (33.3% vs. 13.3%, p=0.004).
Figure 4 describes good correlations between the panel
reactivity of maternal and fetal anti-HLA class I and II antibodies
(for anti-HLA class I antibodies: r = 0.578, p,0.001; for anti-HLA
class II antibodies: r = 0.358, p,0.001). The correlation between
the panel reactivity of maternal and fetal anti-HLA class I and II
antibodies was significant in each group of normal term births and
spontaneous preterm births, respectively (p,0.01, for each).
The presence of alloimmune anti-HLA antibodies in fetal
circulation led us to investigate whether there is antibody-
dependent complement activation in the fetus as a demonstration
of antibody-mediated allograft rejection. Immunohistochemical
staining for C4d was performed using umbilical cord sections
obtained from term in labor (n = 70) and preterm labor (n = 70)
cases. Figure 5 shows C4d deposition on umbilical vein
endothelium. Distinct C4d immunoreactivity confined to umbilical
vein endothelium, but not in umbilical arterial endothelium, was
found in 77.1% (54/70) of preterm labor cases. In contrast, C4d
immunoreactivity was observed only in 11.4% (8/70) of term labor
cases, showing stark contrast with preterm labor cases (p,0.001).
In addition, C4d deposition in umbilical vein endothelium was
significantly associated with the presence of chronic chorioamni-
onitis (75.9% vs. 36.0%, p,0.001), and also tended to be more
frequent in anti-HLA class I seropositive fetuses compared to
seronegative fetuses (60.0% vs. 40.0%, p= 0.051).
Logistic regression analysis was done to determine the respective
risk of placental pathology, maternal and fetal anti-HLA
seropositivity, and C4d immunoreactivity for preterm labor. The
analysis showed that chronic chorioamnionitis (OR: 6.10, 95% CI
1.29–28.83, p = 0.023), maternal vascular underperfusion (OR:
21.32, 95% CI 1.63–278.75, p= 0.02), maternal anti-HLA class I
seropositivity (OR: 5.90, 95% CI 1.60–21.83, p= 0.008), and C4d
deposition on umbilical vein endothelium (OR: 36.19, 95% CI
11.42–114.66, p,0.001) increased the odds of preterm labor and
preterm birth.
Discussion
The principal findings of this study are: (1) maternal anti-HLA
class I seropositivity in spontaneous preterm births is higher than
that of normal term births; (2) mothers with chronic chorioam-
nionitis and villitis of unknown etiology have significantly higher
anti-HLA class I seropositivity than those without these lesions;
(3) C4d immunoreactivity on umbilical vein endothelium,
evidence of the activation of the classical pathway of the
complement system, is a common feature of preterm but not
term labor; and (4) chronic chorioamnionitis, maternal anti-HLA
class I seropositivity, and umbilical vein endothelial C4d increase
the odds ratio of spontaneous preterm birth.
The positive rate of anti-paternal cytotoxic antibody testing
against a partner’s lymphocytes increases as a function of
gestational age in normal pregnant women [22]. This study
demonstrates the potential importance of maternal anti-fetal
antibody-mediated rejection in human spontaneous preterm birth
for the first time. It also establishes a solid and novel link between
the presence of maternal antibody-mediated rejection and chronic
chorioamnionitis, a major pathology in spontaneous preterm birth
[18]. Chronic chorioamnionitis and villitis of unknown etiology
are associated with systemic changes in T cell chemokines in the
fetus [17,18]. However, the precise mechanisms for this associa-
tion between these placental inflammatory lesions and fetal
systemic inflammatory response have remained elusive. Maternal
IgG can cross the placenta [33], and this humoral variety of
alloimmune reaction, in essence, would have a greater chance of
inducing a systemic reaction in the fetus. A murine model of
125I-labeled monoclonal anti-paternal MHC antibody injection
into pregnant mice clearly demonstrated accumulation of the
Figure 1. Histological features of chronic chorioamnionitis.
(A) A case of spontaneous preterm birth showing destruction of the
chorionic trophoblast layer by infiltrating lymphocytes. (B) In another
case of spontaneous preterm birth, lymphocytic infiltration extended to
the chorioamniotic connective tissue layer. Original magnification X200.
doi:10.1371/journal.pone.0016806.g001
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antibodies in various fetal tissues, particularly in blood, thymus,
and liver [34]. Accumulation of intact antibodies in fetal tissues
persisted up to three days after injection, while those were
eliminated in the mother. In humans, examples of neonatal
alloimmune thrombocytopenia due to anti-HLA antibodies
provide compelling evidence that anti-HLA alloimmunity could
have systemic consequences in the fetus [29,35,36]. Of note,
Althaus et al described an association between chronic villitis and
Figure 2. Panel-reactive anti-HLA seropositivity in maternal and fetal sera. (A) A representative case showing the presence of anti-HLA class
I antibodies and the absence of anti-HLA class II antibodies in maternal serum with FlowPRAH-I and -II screening tests, followed by flow cytometry.
(B) Spontaneous preterm birth cases have a higher maternal anti-HLA class I seropositivity than normal term birth cases (p,0.01). TB, normal term
birth; sPTB, spontaneous preterm birth.
doi:10.1371/journal.pone.0016806.g002
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Figure 3. Comparisons of maternal and fetal panel-reactive anti-HLA class I and II seropositivity according to presence or absence
of placental pathologic lesions. Maternal anti-HLA class I and class II seropositivity and fetal anti-HLA class I seropositivity is higher in chronic
chorioamnionitis cases than those without chronic chorioamnionitis (p,0.05, for each). Similarly, maternal anti-HLA class I and class II seropositivity
and fetal anti-HLA class I seropositivity is higher in villitis of unknown etiology cases than those without (p,0.001, for each). Such differences in anti-
HLA seropositivity are not found in the cases with acute chorioamnionitis, maternal vascular underperfusion, and fetal vascular thrombo-occlusive
disease except for maternal anti-HLA class I seropositivity in cases with maternal vascular underperfusion (p,0.05). CCA, chronic chorioamnionitis;
VUE, villitis of unknown etiology; ACA, acute chorioamnionitis; MVU, maternal vascular underperfusion; FVTOD, fetal vascular thrombo-occlusive
disease. *, p,0.05; **, p,0.01; ***, p,0.001.
doi:10.1371/journal.pone.0016806.g003
Figure 4. Correlation between maternal and fetal anti-HLA class I and class II antibodies. The panel reactivity of maternal anti-HLA
antibodies is associated with that of fetal anti-HLA antibodies (for anti-HLA class I antibodies: r = 0.578, p,0.001; for anti-HLA class II antibodies:
r = 0.358, p,0.001). PRA, panel-reactive anti-HLA antibodies.
doi:10.1371/journal.pone.0016806.g004
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Figure 5. C4d deposition on fetal umbilical vein endothelium by immunohistochemistry. C4d immunoreactivity on fetal umbilical vein
endothelium is found in 54 out of 70 cases with preterm labor and intact membranes followed by preterm birth. However, there are only eight C4d
positive cases among 70 cases with normal term labor (77.1% vs. 11.4%; p,0.001). PTL, preterm labor and intact membranes and preterm birth;
TIL, term labor and normal term birth.
doi:10.1371/journal.pone.0016806.g005
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neonatal alloimmune thrombocytopenia [37]. When they com-
pared the placental findings of 14 pregnant women who were
treated or untreated with antepartum intravenous immunoglob-
ulin, chronic villitis was found in 83% (5/6) of the untreated group
while none of the treated cases (0/8) had chronic villitis. Gu et al
also showed that patients with active immune thrombocytopenia
have elevated plasma CXCL10 concentration and higher
CXCL10 mRNA expression in peripheral blood mononuclear
cells compared to normal healthy subjects [38]. These observa-
tions support a link between anti-HLA antibodies and chronic
chorioamnionitis and villitis of unknown etiology.
Anti-HLA class I seropositivity, higher than anti-HLA class II
seropositivity observed in this study, is intriguing. Sensitization to
allo-HLA antigens can follow previous pregnancy, blood transfu-
sion, and organ transplantation [16,39]. Possible explanations
for maternal sensitization against fetal HLA antigens would be:
1) recognition of fetal HLA antigens expressed in the remnants of
trophoblasts or in the chorioamniotic membranes by maternal
effector cells during the cleaning up of the uterine cavity after
delivery [40], 2) feto-maternal hemorrhage [41,42], and 3) fetal
cell trafficking into the mother [43]. Direct or indirect interactions
between fetal and maternal cells occur in the chorionic villi and
the chorioamniotic membranes [44], and evidence for trafficking
of fetal antigens to maternal secondary lymphoid organs has been
demonstrated [43]. As HLA class I antigens are more ubiquitously
expressed in various cell types compared to HLA class II antigens,
this could explain why anti-HLA class I seropositivity is higher in
pregnant women. It is noteworthy that HLA-C but not HLA class
II expression can be detected in the chorionic trophoblasts [44,45].
Interestingly, the significance of alloimmune antibodies has been
studied largely in recurrent miscarriage, yet it remains controver-
sial [21–27]. While earlier studies have reported that the absence
or low titer of anti-paternal cytotoxic antibodies are associated
with recurrent miscarriages [25,26], a recent study does not
support an association between unexplained recurrent miscarriage
and anti-HLA antibodies [24]. Therefore, systematic comparative
analysis of spontaneous preterm birth and spontaneous abortion
would be an important subject of future investigations.
A stark difference in umbilical venous endothelial C4d
immunoreactivity between term and preterm birth cases is also
robust. C4d deposition on endothelium is a surrogate marker of
antibody-mediated rejection in organ transplantation [46]. In the
current study, we determined anti-HLA antibodies in maternal
and fetal sera and C4d deposition on umbilical vein endothelium
for the evaluation of antibody-mediated rejection, and both of
them increase the odds ratio of the occurrence of preterm birth.
Recently, a National Institutes of Health consensus conference
proposed four stages of chronic antibody-mediated rejection: stage
I) latent humoral response (the presence of circulating alloanti-
body); stage II) silent humoral rejection (stage I plus detection of
C4d); stage III) subclinical humoral rejection (stage II plus tissue
injury or pathological change in graft); and stage IV) clinical
humoral rejection (stage III plus graft dysfunction) [47,48]. Anti-
HLA antibodies in maternal and fetal sera and C4d deposition in
umbilical vein endothelial cells in the current study could be
considered stage I or II antibody-mediated rejection, while chronic
chorioamnionitis, villitis of unknown etiology, and spontaneous
preterm birth could be analogous to stage III or IV antibody-
mediated rejection. While anti-HLA seropositivity and C4d show
good correlations in organ transplantation [49,50], we found a
marginal association between fetal anti-HLA class I antibodies and
C4d deposition on umbilical vein endothelium in this study.
Therefore, it would be worthwhile to study roles of other non-
HLA antibodies such as anti-endothelial antibodies and non-
classical MHC class I-related chain A (MICA)-specific alloanti-
bodies in C4d deposition in spontaneous preterm birth [51–54].
During pregnancy, women are also primed to minor histocom-
patibility (H) antigens such as HA-1, HA-2, and HY antigens with
subsequent generation of H antigen-specific CD8+ cytotoxic T
cells [55,56]. Anti-HY immunity was also shown to be associated
with recurrent miscarriages and placental abruption [57]. Of note,
a recent study of 66,387 women demonstrated a higher rate of
preterm delivery in male fetuses due to an increase in spontaneous
preterm labor and preterm prelabor rupture of membranes [58].
There are limitations of this cross-sectional study. We could not
determine the potential impact of dynamic changes in the anti-
HLA antibodies status before and during pregnancy on the
development of spontaneous preterm birth, and further studies on
a longitudinal basis will be needed to address this issue. Another
limitation is that this clinical analysis does not provide a direct
mechanistic link between anti-fetal rejection and the clinical
presentation: preterm labor and preterm prelabor rupture of
membranes. This study was also restricted to the analysis of
spontaneous preterm births. Because medically indicated preterm
birth due to conditions such as preeclampsia and fetal growth
restriction comprises a substantial proportion of preterm births
and because chronic chorioamnionitis is also observed in these
pregnancy complications, future studies on the antibody-mediated
rejection in the setting of indicated preterm birth are required.
Collectively, we propose that a subset of spontaneous preterm
birth has a signature of maternal anti-fetal rejection, in which the
phenotypic complex of cellular rejection is comprised of chronic
chorioamnionitis and villitis of unknown etiology coupled with
graft-versus-host disease of the fetus [17,18]. The phenotype of
antibody-mediated rejection is generation of anti-paternal/fetal
antibodies in the mother and fetal alloimmune reaction due to
these antibodies and complement activation. Although human
pregnancy displays many analogous features to allograft trans-
plantation, it also poses a very unique biological situation because
the fetus is another host with isolated circulation from the mother.
Novel findings herein have profound implications in understand-
ing the biology of preterm birth and developing preventive and
therapeutic modalities.
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